Bayer AG’s failure to identify weaknesses in Merck & Co.’s over the counter drug business before it bought it in 2014 sets a problematic precedent for its latest acquisition, an M&A expert told me today. Why? Read my piece for the Wall Street Journal’s CFO Journal.
U.S.-based pharma still banking on new British digs, WSJ
No firefighting but fundamental changes ahead for new BMW CFO, WSJ
Corporate Bond Buying attracts doubts as growth tool, WSJ
After Paying Off Debt, Lanxess will take on more, WSJ
Pile of debts awaits new Anglo American CFO, WSJ
New Rolls-Royce CFO Faces tricky accounting, WSJ
Bayer’s diligence failure haunts its Monsanto purchase, WSJ
Figuring out GAAP is not the only challenge, WSJ
A U.S. investigation into the lack of write-downs at Exxon Mobil Corp. despite the slump in oil-prices has brought to light the challenge of assessing impairments under U.S. Generally Accepted Accounting Principles (GAAP). But, for international companies and U.S. firms with foreign operations, figuring out GAAP is not the only contest. For the Wall Street Journal’s CFO Journal, I have taken a closer look at write-downs under GAAP vs. IFRS.
Hinkley Deal Could Be Make or Break For EDF, Analysts Say, WSJ
Finally! The British government has given the green light for the new nuclear reactor in Somerset. The project could either bolster or wreck EDF, the majority shareholder. Why? I have taken a closer look at the financials of the deal.